281 related articles for article (PubMed ID: 11424549)
1. The effects of antiretroviral protease inhibitors on serum lipid levels in HIV-infected patients.
Chang ES; Tetreault DD; Liu YT; Beall GN
J Am Diet Assoc; 2001 Jun; 101(6):687-9. PubMed ID: 11424549
[No Abstract] [Full Text] [Related]
2. Hyperlipidemia associated with the use of protease inhibitors.
Smith JH; Martin GJ; Decker CF
Clin Infect Dis; 2000 Jul; 31(1):207-8. PubMed ID: 10913432
[No Abstract] [Full Text] [Related]
3. [Diabetes and hyperglycemia in patients under treatment for HIV infection with the protease inhibitors indavir, ritonavir, saquinavir as well as nelfinavir (in development, but not yet released].
Pharm Unserer Zeit; 1997 Dec; 26(6):317. PubMed ID: 9513575
[No Abstract] [Full Text] [Related]
4. Disorders of lipid metabolism in patients with HIV disease treated with antiretroviral agents: frequency, relationship with administered drugs, and role of hypolipidaemic therapy with bezafibrate.
Manfredi R; Chiodo F
J Infect; 2001 Apr; 42(3):181-8. PubMed ID: 11545549
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
[No Abstract] [Full Text] [Related]
6. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study.
Périard D; Telenti A; Sudre P; Cheseaux JJ; Halfon P; Reymond MJ; Marcovina SM; Glauser MP; Nicod P; Darioli R; Mooser V
Circulation; 1999 Aug; 100(7):700-5. PubMed ID: 10449690
[TBL] [Abstract][Full Text] [Related]
7. Marked hyperlipidaemia on ritonavir therapy.
Sullivan AK; Nelson MR
AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
[No Abstract] [Full Text] [Related]
8. The safety and antiviral effect of protease inhibitors in children.
Temple ME; Koranyi KI; Nahata MC
Pharmacotherapy; 2001 Mar; 21(3):287-94. PubMed ID: 11253853
[TBL] [Abstract][Full Text] [Related]
9. Type 2 diabetes in association with HIV-1 protease inhibitors in HIV-infected patients.
Chronister CL; Gurwood AS
J Am Optom Assoc; 1998 Nov; 69(11):695-8. PubMed ID: 9844321
[No Abstract] [Full Text] [Related]
10. HIV protease inhibitors: advances in therapy and adverse reactions, including metabolic complications.
Kaul DR; Cinti SK; Carver PL; Kazanjian PH
Pharmacotherapy; 1999 Mar; 19(3):281-98. PubMed ID: 10221367
[TBL] [Abstract][Full Text] [Related]
11. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
[TBL] [Abstract][Full Text] [Related]
12. Double boosted protease inhibitors, saquinavir, and lopinavir/ritonavir, in nucleoside pretreated children at 48 weeks.
Kosalaraksa P; Bunupuradah T; Engchanil C; Boonrak P; Intasan J; Lumbiganon P; Burger D; Ruxrungtham K; Schutz M; Ananworanich J;
Pediatr Infect Dis J; 2008 Jul; 27(7):623-8. PubMed ID: 18520443
[TBL] [Abstract][Full Text] [Related]
13. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
[TBL] [Abstract][Full Text] [Related]
14. Effect of protease inhibitors on the sense of taste.
Schiffman SS; Zervakis J; Heffron S; Heald AE
Nutrition; 1999 Oct; 15(10):767-72. PubMed ID: 10501290
[TBL] [Abstract][Full Text] [Related]
15. A patient's guide to protease inhibitors.
Elperin A; Sax P
AIDS Clin Care; 1996 Oct; 8(10):83-4. PubMed ID: 11363988
[TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
[TBL] [Abstract][Full Text] [Related]
17. Hyperlipidemia under treatment with proteinase inhibitors.
Segerer S; Bogner JR; Walli R; Loch O; Goebel FD
Infection; 1999; 27(2):77-81. PubMed ID: 10219634
[TBL] [Abstract][Full Text] [Related]
18. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?
Fontas E; van Leth F; Sabin CA; Friis-Møller N; Rickenbach M; d'Arminio Monforte A; Kirk O; Dupon M; Morfeldt L; Mateu S; Petoumenos K; El-Sadr W; de Wit S; Lundgren JD; Pradier C; Reiss P;
J Infect Dis; 2004 Mar; 189(6):1056-74. PubMed ID: 14999610
[TBL] [Abstract][Full Text] [Related]
19. The long-term pharmacokinetics and safety of adding low-dose ritonavir to a nelfinavir 1,250 mg twice-daily regimen in HIV-infected patients.
Justesen US; Hansen IM; Andersen AB; Klitgaard NA; Black FT; Gerstoft J; Mathiesen LR; Pedersen C
HIV Med; 2005 Sep; 6(5):334-40. PubMed ID: 16156881
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of two randomized trials evaluating the safety and efficacy of indinavir, saquinavir and lopinavir in combination with low-dose ritonavir: the MaxCmin1 and 2 trials.
Justesen US; Fox Z; Pedersen C; Cahn P; Gerstoft J; Clumeck N; Losso M; Peters B; Obel N; Castagna A; Dragsted UB; Lundgren JD;
Basic Clin Pharmacol Toxicol; 2007 Nov; 101(5):339-44. PubMed ID: 17910618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]